{"id":"W2551196508","doi":"10.1182/blood.v110.11.4587.4587","title":"Short-Term Cost Per Responder among New Tyrosine Kinase Inhibitors for Imatinib-Resistant CML in Chronic Phase (CML-CP) — Canada and Germany Perspectives.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Dasatinib; Nilotinib; Medicine; Imatinib; Internal medicine; Oncology; Cost effectiveness; Drug holiday; Adverse effect; Tyrosine-kinase inhibitor; Surrogate endpoint; Imatinib mesylate; Pharmacology; Immunology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00177997,0.0006275408,0.0005673987,0.002191662,0.000795607,0.002728052,0.001051562,0.0008002651,0.004977485],"category_scores_gemma":[0.003707739,0.0002777112,0.001415721,0.004040086,0.0003504647,0.001005362,0.0006365579,0.001053963,0.0002342819],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.06411164,"about_ca_system_score_gemma":0.0464079,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9619555,"about_ca_topic_score_gemma":0.9630221,"domain_scores_codex":[0.9983708,0.0003623576,0.00007757276,0.0001549879,0.0006547078,0.0003794993],"domain_scores_gemma":[0.9977804,0.0003194462,0.0001849047,0.0000325333,0.001407043,0.0002757222],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.003767625,0.0005437041,0.187954,0.002622426,0.002416176,0.001891341,0.0008667607,0.2526208,0.002066673,0.1296606,0.08543221,0.3301577],"study_design_scores_gemma":[0.0007294171,0.001284217,0.5410661,0.002898881,0.002817484,0.001479491,0.00441673,0.2355105,0.00268589,0.01137783,0.1952518,0.0004817485],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6493496,0.06786603,0.01213687,0.05358494,0.0009911332,0.0008640518,0.09002151,0.0001947732,0.124991],"genre_scores_gemma":[0.9517869,0.01566864,0.005150438,0.001009603,0.0001444647,0.0001312605,0.009241253,0.00005313839,0.01681419],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06411164,"threshold_uncertainty_score":0.4651647,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01463464178898941,"score_gpt":0.2921615973560873,"score_spread":0.2775269555670978,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}